+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Can postoperative radiotherapy be omitted in localised standard-risk Ewing sarcoma? An observational study of the Euro-E.W.I.N.G group



Can postoperative radiotherapy be omitted in localised standard-risk Ewing sarcoma? An observational study of the Euro-E.W.I.N.G group



European Journal of Cancer 61: 128-136



The role of postoperative radiotherapy (PORT) in Ewing sarcoma (ES) is unclear. We assessed the impact of PORT on local control in patients with localised ES and good histological response to chemotherapy (<10% cells). All randomised patients in the EE99-R1 trial (comparing two consolidation chemotherapy regimens) undergoing surgery after induction chemotherapy were included. Local relapse (LR) cumulative incidence was estimated using a competing risk approach. Impact of PORT was assessed in multivariable models, adjusted for country, age, tumour site and volume, quality of resection and histological response. We also evaluated the heterogeneity of PORT effect by patient and tumour characteristics. One hundred forty-two (24%) of the 599 patients included from 1999 to 2009 received PORT (median dose: 45 Grays). With median follow-up of 6.2 years, 67 patients had an LR (with concomitant metastases in 28), leading to an 8-year LR-incidence = 11.9% (standard error [se] = 1.4%). Overall survival (OS) = 21% (se = 5%) 3 years after LR (31% in isolated LR). Controlling for possible confounders, we observed a statistically significant reduction of LR in patients treated by surgery + PORT compared to surgery alone (subdistribution-hazard ratio = 0.43, 95% confidence interval, 0.21-0.88, p = 0.02). The benefit of PORT was particularly marked for tumours larger than 200 ml at diagnosis and 100% necrosis. We observed a non-significant trend for benefit associated with PORT for disease-free, event-free and OS. Radiotherapy appears to improve local control. We now recommend PORT in case of incomplete removal of the tissues involved by the pre-chemotherapy tumour volume. Further studies are required to assess the balance between benefit and risks.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057347587

Download citation: RISBibTeXText

PMID: 27176931

DOI: 10.1016/j.ejca.2016.03.075


Related references

Is postoperative radiotherapy necessary in localised standard-risk Ewing sarcoma? : The primary tumor bulk decides upon adjuvant radiotherapy after induction chemotherapy and surgery. Strahlentherapie und Onkologie 193(1): 89-90, 2017

High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008. Journal of Clinical Oncology 2018: Jco2018782516, 2018

Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial. Journal of Clinical Oncology 32(23): 2440-2448, 2014

Adjuvant chemotherapy and postoperative radiotherapy in high-risk soft tissue sarcoma patients defined by biological risk factors-A Scandinavian Sarcoma Group study (SSG XX). European Journal of Cancer 99: 78-85, 2018

Results for patients with sarcoma not otherwise specified and other diagnoses than Ewing sarcoma treated according to the Euro-EWING 99 trial. Pediatric Blood and Cancer 64(10):, 2017

Risk adapted chemotherapy for localised Ewing's sarcoma of bone: the French EW93 study. European Journal of Cancer 48(9): 1376-1385, 2012

Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. Journal of Clinical Oncology 28(20): 3284-3291, 2010

Local control in Ewing sarcoma of the chest wall: results of the EURO-EWING 99 trial. Annals of Surgical Oncology 22(9): 2853-2859, 2015

Late effects of chemotherapy and radiotherapy in osteosarcoma and Ewing sarcoma patients: the Italian Sarcoma Group Experience (1983-2006). Cancer 118(20): 5050-5059, 2012

Local therapy and other factors influencing site of relapse in patients with localised Ewing's sarcoma. United Kingdom Children's Cancer Study Group (UKCCSG). European Journal of Cancer 35(12): 1698-1704, 1999

Results of the EICESS-92 Study: Two Randomized Trials of Ewing's Sarcoma TreatmentCyclophosphamide Compared With Ifosfamide in Standard-Risk Patients and Assessment of Benefit of Etoposide Added to Standard Treatment in High-Risk Patients. Yearbook of Oncology 2009: 167-168, 2009

A phase II window study of irinotecan (CPT-11) in high risk Ewing sarcoma: a Euro-E.W.I.N.G. study. Pediatric Blood and Cancer 61(3): 442-445, 2014

Radiation therapy in the multimodality management of Ewing's Sarcoma of bone A report of the intergroup EWING'S SARCOMA study group. International Journal of Radiation Oncology*biology*physics 5(Supp-S2): 99-0, 1979

Ewing's sarcoma and primitive neuroectodermal tumor of hand and forearm. Experience of the Cooperative Ewing's Sarcoma Study Group. Journal of Cancer Research and Clinical Oncology 131(4): 219-225, 2005

Prognostic factors in the treatment of Ewing's sarcoma. The Ewing's Sarcoma Study Group of the German Society of Paediatric Oncology CESS 81. RadioTherapy and Oncology 10(2): 101-110, 1987